XClose

Centre for Amyloidosis and Acute Phase Proteins

Home
Menu

National Amyloidosis Centre

Head/Clinical DirectorProfessor Philip Hawkins020 7433 2815/2816
   
Emeritus Professor/ConsultantProfessor Sir Mark Pepys020 7433 2801/2802
   
Professor/ConsultantProfessor Julian Gillmore020 7433 2726
   
Readers/Senior Lecturers/ConsultantsDr Marianna Fontana020 7433 2764
 Dr Helen Lachmann020 7433 2804
 Dr Ashutosh Wechalekar020 7433 2758
 Dr Carol Whelan020 7433 2789
   
Locum Consultants/Clinical FellowsDr Shameem Mahmood  020 7433 2770
 Dr Richa Manwani020 7433 2733
 Dr Ana Martinez020 7433 2777
 Dr Cristina Quarta 020 7433 2789
 Dr Tamer Rezk 020 7433 2823
 Dr Sajitha Sachchithanantham020 7433 2778
 Dr Faye Sharpley020 7433 2763
   
Specialist/Research NursesDarren Foard020 7433 2814
 Rene Williams020 7433 2797
   
Clinic CoordinatorEleanor Pyart020 7433 2738
   
Centre ManagerAdrian Machinn020 7433 2732
   
Appointments &
Office Manager
Ramon Lamarca020 7433 2813
   
Centre Administrator/Academic PAJean Berkeley020 7433 2816
   
Medical SecretariesSarah Louth020 7433 2737/2798/2811
Transport & AccommodationOnana Ayissi020 7433 2812
General Enquiries 020 7433 2725
Fax 020 7433 2817


The NHS National Amyloidosis Centre is the only centre in the UK specialising in amyloidosis and is part of University College London Centre for Amyloidosis and Acute Phase Proteins, one of the world's leading centres for amyloid research. The Centre has "state of the art" clinical and research facilities, and a team of highly qualified clinical, research and support staff.

We pioneered scintigraphic imaging (scanning) of amyloid as a quantitative diagnostic procedure and provide a comprehensive clinical service for patients with all types of acquired and hereditary systemic amyloidosis.  The NHS National Amyloidosis Centre is commissioned by NHS National Specialised Services and funded by the Department of Health to provide a diagnostic and management advice service for the UK's national caseload of patients with amyloidosis and related disorders.  We have evaluated over 10,000 patients. The clinical service includes:

    • Detailed clinical assessment.
    • Diagnosis, quantification and monitoring of amyloidosis with whole body SAP scintigraphy.
    • Comprehensive expert diagnostic and monitoring studies of the heart, as required, by cardiac magnetic resonance, echocardiography and DPD scanning.
    • Review of diagnostic biopsies and specialised immunohistochemistry to determine amyloid type.
    • Characterisation and exclusion of hereditary amyloidosis by DNA testing; genetic counselling.
    • Measurement and monitoring of specialised biochemical (blood) tests for serum free light chains and serum amyloid A protein.
    • Recommendations for treatment and monitoring response.
    • 3‑12 monthly follow‑up to assess response and further treatment requirements. Sometimes follow‑up assessment can be performed by telephone if patients live far away.
    • Providing information and support to amyloidosis patients, their families and health providers.
    • Systematic evaluation of existing and new treatments.
    • Diagnosis, monitoring and treatment of inherited fever syndromes.